

Moderator:

Anil Goyal, PhD, OpenDoors Group

Dr. Goyal is founder and managing director of consulting firm OpenDoors Group. During the last 20 years, he's been part of the leadership teams at 3 public and 3 private biotechnology companies that were primarily oncology focused. He is currently fractional VP of Business Development at MimiVax, LLC, (an immuno-oncology company with Phase II program for glioblastoma) and Esanex Inc., (with an oral Hsp90 inhibitor entering Phase II for lung cancer). Prior to these companies, he served as VP of Business Development at Heat Biologics (HTBX) immuno-oncology company. From 2010-13 he served as CEO and co-founder of Qualiber, Inc., a cancer nanomedicine company launched from UNC-CH. Other companies during his career included: Ascleris Pharmaceuticals (Hangzhou), Ophtherion, Serenex (Acquired by Pfizer), Millennium Pharma (Acq. by Takeda), Osient Pharma, and Merck & Co.

Dr. Goyal received his Ph.D. in Microbiology and Molecular Genetics jointly from Rutgers, The State University and University of Medicine and Dentistry of New Jersey, and is a Certified Licensing Professional (CLP™) by the Licensing Executives Society, Inc.

Panelists:

Scott Weiner, MBA, Partner, Pappas Ventures

Prior to joining Pappas Ventures in 2006, Scott was an investment manager and research analyst for Silverback Asset Management's life science fund, where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners (formerly William Blair Capital Partners) as a Vice President focusing on healthcare venture capital investments. Previously, he spent three and a half years in investment banking at Lehman Brothers. There, he worked in the healthcare group in New York covering biotechnology, medical devices and drug delivery; the financial sponsors/leveraged finance group in London; and the media/telecom group in Hong Kong.

Scott currently serves as a director for Gentis, Milestone Pharmaceuticals and Rotation Medical; and as an observer for Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics. He previously served as a board observer for LipoScience (NASDAQ: LPDX), and TESARO (NASDAQ: TSRO). Scott has a BS in Biological Anthropology and Anatomy and an MBA from Duke University.



Anita Watkins, JD, Director, REX Strategic Innovations

Anita joined REX in 2012 to help launch REX Strategic Innovations. She is a member of the REX Health Ventures team and oversees REX Health Solutions working to partner with health care innovators to pilot emerging healthcare solutions within the hospital. Prior to joining REX, she served as the Vice President for Government Relations for UNC General Administration.

She received her Juris Doctorate and Master of Regional Planning from the University of North Carolina at Chapel Hill and undergraduate degrees in Political Science and Spanish from North Carolina State University.



Jonathan Meltzer, MBA, Senior Vice President, LabCorp Ventures

Jon Meltzer is a Senior Vice President at LabCorp responsible for the Specialty Oncology Businesses, LabCorp Ventures and select R&D initiatives. Jon joined LabCorp in 2006 has held multiple and often overlapping roles including: Executive Lead for Covance Food Solutions, SVP of Corporate Strategy, President of Enlighten Health, VP/GM of Litholink & next gen sequencing and VP of Corporate Development. Before joining LabCorp, Jon held positions with Pappas Ventures, the Duke Office of Licensing and Ventures, the North Carolina Department of the State Treasurer, the National Research Council of Canada Institute for Biodegnostics and co-founded a company that manufactured molecular reagents for biomedical research.

Jon received his MBA from the Duke University Fuqua School of business in 2006 and his Ph.D. from the University of Manitoba in 2000.



Alex Gray, MBA - Principal, Market Development, Echo Health Ventures

Alex is a Principal, Market Development at Echo Health Ventures. Previously, Alex led the business development team at Mosaic Health Solutions where he was involved in deals from start to finish - from identifying investment opportunities to serving as an operating partner for Mosaic's portfolio of venture and growth stage companies. Alex and his team work closely with portfolio executive teams in identifying and implementing growth strategies aimed at accelerating value creation and health innovation.

Prior to his role at Mosaic, Alex was a manager in Deloitte Consulting's mergers & acquisitions group, working primarily on M&A strategy, day-one readiness planning, post-merger integration, and operational carve-outs for large transactions in the consumer product, healthcare, and finance industries. Prior to Deloitte, Alex was a senior associate at Tower Capital, a long/short equity fund-of-funds. He began his career at Zolfo Cooper, a leading financial advisory and interim management firm providing restructuring leadership to distressed companies and their stakeholders.

Alex holds a bachelor's degree in economics from Bowdoin College and an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. In addition, he serves on the board of the Durham Literacy Center, which provides free literacy services to adults and out-of-school youth in Durham County. Outside of the office, Alex enjoys exploring North Carolina with his wife and three young children.



Michael Dial, PhD – Principal, Hatteras Venture Partners

Prior to joining Hatteras, Mike was a Vice President in Silicon Valley Bank's Corporate Finance Group where he focused on emerging life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

Mike is also the Manager of the Carolina Research Ventures Fund, a fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.